Acrux is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin. Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing. Acrux's product pipeline includes treatment of hormonal deficiencies, central nervous system disorders, contraception and dermatological conditions. The first product is being marketed in the USA by Acrux's licensee following approval by the US Food and Drug Administration (FDA).

Therapeutics (“Aegis”) is a specialty pharmaceutical company commercializing advanced patented drug delivery and protein stabilization technologies that enable the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular therapeutics. Our goal is to broadly enable intranasal and transmucosal delivery of peptide and protein drugs across a wide spectrum of disease categories for the world’s current and future leading pharmaceutical and biopharmaceutical companies.